Scott Jeffers
Chief Technology Officer GenSight Biologics
Scott Jeffers, Ph.D., is Chief Technology Officer at GenSight Biologics, where he leads global CMC strategy for AAV-based gene therapy programs, including the commercial development of LUMEVOQ® for Leber Hereditary Optic Neuropathy. With over 20 years of experience in gene therapy and viral vector development, Dr. Jeffers has held senior roles at uniQure, Selecta Biosciences, and Brammer Bio, contributing to the launch of Hemgenix®, the first FDA-approved gene therapy for hemophilia B.
His scientific background includes doctoral research at Purdue University (three U.S. patents in viral vector design), discovery of the SARS-CoV receptor CD209L at the University of Colorado, and structural virology research at the Institut Pasteur, published in Science and PLOS Pathogens.
Dr. Jeffers also founded CGT Resources Now LLC, advising biopharma companies on manufacturing strategy, comparability, and regulatory readiness. A frequent speaker at global bioprocessing conferences, he is recognized for advancing innovation and reliability in gene therapy manufacturing.
Seminars
- Streamlining validation package requirements and Process Performance Qualification (PPQ) batch strategies to reduce multi-million-dollar costs that threaten program viability for single-asset developers
- Balancing regulatory compliance with practical cost constraints for small companies, implementing efficient approaches that meet agency standards without excessive financial burden
- Implementing efficient process development strategies that achieve regulatory approval while preserving capital for clinical trials and commercial launch preparation
